Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms

The Duke cerebrovascular center experience in 235 patients with 274 stents

Mark L. Lessne, Pratish Shah, Michael J. Alexander, Huiman X. Barnhart, Ciaran J. Powers, Kiarash Golshani, Andrew Ferrell, David Enterline, Ali Zomorodi, Tony Smith, Gavin W. Britz

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND: The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement. OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement. METHODS: A total of 235 patients were treated with 274 Neuroform stents. The thromboembolic event rate was determined by imaging or clinical evidence of cerebrovascular accident within 90 days of stent placement; for patients with incomplete follow-up through chart review, telephone interviews were conducted. Analyses were performed to investigate patient factors that may be associated with stroke. RESULTS: Most aneurysms were unruptured; 30 patients (12.8%) presented with acute subarachnoid hemorrhage. Twelve patients of the 224 with follow-up (5.4%, 95% confidence interval: 2.4%-8.3%) demonstrated imaging or clinical evidence of a new thromboembolic event within 90 days of stent placement. There was a 3.1% thromboembolic rate for unruptured aneurysms and a 20% rate in patients with subarachnoid bleed. Hemorrhage was significantly associated with having a thromboembolic event (P = .002). There was a trend toward an increased thromboembolic event rate for patients with hypertension (P = .07). Larger stent caliber was significantly associated with a decreased thromboembolic event rate (P = .032). CONCLUSION: Our results suggest that the thromboembolic event rate associated with Neuroform stent use is low in unruptured aneurysms. In ruptured aneurysms, the complication rate is high, possibly partly related to restricted use of antiplatelet therapy. Stent size and hypertension may be associated with the risk of stroke, but additional studies are needed to confirm their significance.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalNeurosurgery
Volume69
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Intracranial Aneurysm
Stents
Aneurysm
Therapeutics
Stroke
Hypertension
Ruptured Aneurysm
Subarachnoid Hemorrhage
Confidence Intervals
Interviews
Hemorrhage
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms : The Duke cerebrovascular center experience in 235 patients with 274 stents. / Lessne, Mark L.; Shah, Pratish; Alexander, Michael J.; Barnhart, Huiman X.; Powers, Ciaran J.; Golshani, Kiarash; Ferrell, Andrew; Enterline, David; Zomorodi, Ali; Smith, Tony; Britz, Gavin W.

In: Neurosurgery, Vol. 69, No. 2, 01.08.2011, p. 369-375.

Research output: Contribution to journalArticle

Lessne, ML, Shah, P, Alexander, MJ, Barnhart, HX, Powers, CJ, Golshani, K, Ferrell, A, Enterline, D, Zomorodi, A, Smith, T & Britz, GW 2011, 'Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms: The Duke cerebrovascular center experience in 235 patients with 274 stents', Neurosurgery, vol. 69, no. 2, pp. 369-375. https://doi.org/10.1227/NEU.0b013e31821bc49c
Lessne, Mark L. ; Shah, Pratish ; Alexander, Michael J. ; Barnhart, Huiman X. ; Powers, Ciaran J. ; Golshani, Kiarash ; Ferrell, Andrew ; Enterline, David ; Zomorodi, Ali ; Smith, Tony ; Britz, Gavin W. / Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms : The Duke cerebrovascular center experience in 235 patients with 274 stents. In: Neurosurgery. 2011 ; Vol. 69, No. 2. pp. 369-375.
@article{b00eccf1bee24b66acdf17f5b3959d07,
title = "Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms: The Duke cerebrovascular center experience in 235 patients with 274 stents",
abstract = "BACKGROUND: The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement. OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement. METHODS: A total of 235 patients were treated with 274 Neuroform stents. The thromboembolic event rate was determined by imaging or clinical evidence of cerebrovascular accident within 90 days of stent placement; for patients with incomplete follow-up through chart review, telephone interviews were conducted. Analyses were performed to investigate patient factors that may be associated with stroke. RESULTS: Most aneurysms were unruptured; 30 patients (12.8{\%}) presented with acute subarachnoid hemorrhage. Twelve patients of the 224 with follow-up (5.4{\%}, 95{\%} confidence interval: 2.4{\%}-8.3{\%}) demonstrated imaging or clinical evidence of a new thromboembolic event within 90 days of stent placement. There was a 3.1{\%} thromboembolic rate for unruptured aneurysms and a 20{\%} rate in patients with subarachnoid bleed. Hemorrhage was significantly associated with having a thromboembolic event (P = .002). There was a trend toward an increased thromboembolic event rate for patients with hypertension (P = .07). Larger stent caliber was significantly associated with a decreased thromboembolic event rate (P = .032). CONCLUSION: Our results suggest that the thromboembolic event rate associated with Neuroform stent use is low in unruptured aneurysms. In ruptured aneurysms, the complication rate is high, possibly partly related to restricted use of antiplatelet therapy. Stent size and hypertension may be associated with the risk of stroke, but additional studies are needed to confirm their significance.",
author = "Lessne, {Mark L.} and Pratish Shah and Alexander, {Michael J.} and Barnhart, {Huiman X.} and Powers, {Ciaran J.} and Kiarash Golshani and Andrew Ferrell and David Enterline and Ali Zomorodi and Tony Smith and Britz, {Gavin W.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1227/NEU.0b013e31821bc49c",
language = "English (US)",
volume = "69",
pages = "369--375",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Thromboembolic complications after neuroform stent-assisted treatment of cerebral aneurysms

T2 - The Duke cerebrovascular center experience in 235 patients with 274 stents

AU - Lessne, Mark L.

AU - Shah, Pratish

AU - Alexander, Michael J.

AU - Barnhart, Huiman X.

AU - Powers, Ciaran J.

AU - Golshani, Kiarash

AU - Ferrell, Andrew

AU - Enterline, David

AU - Zomorodi, Ali

AU - Smith, Tony

AU - Britz, Gavin W.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - BACKGROUND: The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement. OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement. METHODS: A total of 235 patients were treated with 274 Neuroform stents. The thromboembolic event rate was determined by imaging or clinical evidence of cerebrovascular accident within 90 days of stent placement; for patients with incomplete follow-up through chart review, telephone interviews were conducted. Analyses were performed to investigate patient factors that may be associated with stroke. RESULTS: Most aneurysms were unruptured; 30 patients (12.8%) presented with acute subarachnoid hemorrhage. Twelve patients of the 224 with follow-up (5.4%, 95% confidence interval: 2.4%-8.3%) demonstrated imaging or clinical evidence of a new thromboembolic event within 90 days of stent placement. There was a 3.1% thromboembolic rate for unruptured aneurysms and a 20% rate in patients with subarachnoid bleed. Hemorrhage was significantly associated with having a thromboembolic event (P = .002). There was a trend toward an increased thromboembolic event rate for patients with hypertension (P = .07). Larger stent caliber was significantly associated with a decreased thromboembolic event rate (P = .032). CONCLUSION: Our results suggest that the thromboembolic event rate associated with Neuroform stent use is low in unruptured aneurysms. In ruptured aneurysms, the complication rate is high, possibly partly related to restricted use of antiplatelet therapy. Stent size and hypertension may be associated with the risk of stroke, but additional studies are needed to confirm their significance.

AB - BACKGROUND: The Neuroform Stent has facilitated the endovascular treatment of wide-necked cerebral aneurysms. It is unknown which factors pose risks of thromboembolic events after stent placement. OBJECTIVE: This series is the largest single-center study reporting on the incidence of and factors influencing thromboembolic complications after Neuroform stent placement. METHODS: A total of 235 patients were treated with 274 Neuroform stents. The thromboembolic event rate was determined by imaging or clinical evidence of cerebrovascular accident within 90 days of stent placement; for patients with incomplete follow-up through chart review, telephone interviews were conducted. Analyses were performed to investigate patient factors that may be associated with stroke. RESULTS: Most aneurysms were unruptured; 30 patients (12.8%) presented with acute subarachnoid hemorrhage. Twelve patients of the 224 with follow-up (5.4%, 95% confidence interval: 2.4%-8.3%) demonstrated imaging or clinical evidence of a new thromboembolic event within 90 days of stent placement. There was a 3.1% thromboembolic rate for unruptured aneurysms and a 20% rate in patients with subarachnoid bleed. Hemorrhage was significantly associated with having a thromboembolic event (P = .002). There was a trend toward an increased thromboembolic event rate for patients with hypertension (P = .07). Larger stent caliber was significantly associated with a decreased thromboembolic event rate (P = .032). CONCLUSION: Our results suggest that the thromboembolic event rate associated with Neuroform stent use is low in unruptured aneurysms. In ruptured aneurysms, the complication rate is high, possibly partly related to restricted use of antiplatelet therapy. Stent size and hypertension may be associated with the risk of stroke, but additional studies are needed to confirm their significance.

UR - http://www.scopus.com/inward/record.url?scp=79960375066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960375066&partnerID=8YFLogxK

U2 - 10.1227/NEU.0b013e31821bc49c

DO - 10.1227/NEU.0b013e31821bc49c

M3 - Article

VL - 69

SP - 369

EP - 375

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 2

ER -